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1424Objective: The presence of pulmonary hypertension historically has been considered a significant risk factor
affecting early and late outcomes after valve replacement. Given the number of recent advances in the manage-
ment of pulmonary hypertension after cardiac surgery, a better understanding of its impact on outcomes may
assist in the clinical management of these patients. The purpose of this study was to determine whether pulmo-
nary hypertension remains a risk factor in the modern era for adverse outcomes after aortic valve replacement for
aortic valve stenosis.
Methods: From January 1996 to June 2009, a total of 1080 patients underwent aortic valve replacement for
primary aortic valve stenosis, of whom 574 (53%) had normal systolic pulmonary artery pressures (sPAP)
and 506 (47%) had pulmonary hypertension. Pulmonary hypertension was defined as mild (sPAP 35–44 mm
Hg), moderate (45–59 mmHg), or severe ( 60 mmHg). In the group of patients with pulmonary hypertension,
204 had postoperative echocardiograms.
Results: Operative mortality was significantly higher in patients with pulmonary hypertension (47/506, 9%, vs
31/574, 5%, P¼ .02). The incidence of postoperative stroke was similar (P¼ .14), but patients with pulmonary
hypertension had an increased median hospital length of stay (8 vs 7 days, P¼ .001) and an increased incidence
of prolonged ventilation (26% vs 17%, P<.001). Preoperative pulmonary hypertension was an independent
risk factor for decreased long-term survival (relative risk 1.7, P ¼ .02). Those with persistent pulmonary
hypertension postoperatively had decreased survival. Five-year survival (Kaplan–Meier) was 78%  6%
with normal sPAP and 77%  7% with mild pulmonary hypertension postoperatively, compared with 64%
 8% with moderate and 45%  12% with severe pulmonary hypertension (P<.001).
Conclusions: In patients undergoing aortic valve replacement, preoperative pulmonary hypertension increased
operative mortality and decreased long-term survival. Patients with persistent moderate or severe pulmonary hy-
pertension after aortic valve replacement had decreased long-term survival. These data suggest that pulmonary
hypertension had a significant impact on outcomes in patients undergoing aortic valve replacement and should
be considered in preoperative risk assessment. (J Thorac Cardiovasc Surg 2011;141:1424-30)Earn CME credits at
http://cme.ctsnetjournals.org
Historically, patients with aortic valve stenosis and pulmo-
nary hypertension (PH) have had impaired left ventricular
function, mitral regurgitation, and increased left ventricular
end-diastolic pressure (LVEDP).1-3 Because of associated
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The Journal of Thoracic and Cardiovascular Surmay increase morbidity and mortality when patients with
aortic valve stenosis undergo valve replacement. Small
observational studies have demonstrated benefit with
aortic valve replacement (AVR) in patients with aortic
stenosis and PH in both symptoms and 5-year survivals
when compared with medically managed patients.2-6 AVR
in these patients may decrease strain on the right heart
with left ventricular unloading, thus improving survival.
However, there have been no large studies to date
characterizing the outcomes of patients with PH despite
the possible increased risks.
Surgery in the setting of PH may carry a higher risk than
in patients without PH owing to fixed vasculopathy and right
heart failure. These comorbid conditions can make postop-
erative care challenging. There has not yet been sufficient
evidence in the literature to define an increase in risk for
patients who undergo AVR for aortic stenosis with PH.
Transcatheter approaches are currently being used to treat
high-risk patients and determination of additional risk posed
by PH may aid in selection of patients for intervention by
surgery, transcatheter approach, or medical treatment alone.gery c June 2011
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
CABG ¼ coronary artery bypass graft
LVEDP ¼ left ventricular end-diastolic pressure
LVEF ¼ left ventricular ejection fraction
PAP ¼ pulmonary artery pressure
PH ¼ pulmonary hypertension
PVR ¼ pulmonary vascular resistance
RR ¼ relative risk
sPAP ¼ systemic pulmonary arterial pressure
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for aortic stenosis from 1996 through 2009 to evaluate long-
term survival and to determinewhether PH is a risk factor in
patients undergoing AVR for aortic stenosis.
PATIENTS AND METHODS
This retrospective study was approved by the Institutional Review
Board of Washington University School of Medicine, and individual con-
sent was waived. Between January 1, 1996, and June 30, 2009, a total of
1777 patients underwent AVR with or without concomitant procedures
(coronary artery bypass graft; mitral, tricuspid, or pulmonary valve repair
or replacement; atrial septal defect repair; ventricular septal defect repair;
or arrhythmia surgery). A total of 697 patients had a Ross procedure, endo-
carditis, aneurysm reconstruction, or aortic regurgitation as the primary di-
agnosis and these were excluded from analysis, leaving 1080 patients for
review. AVR was performed in accordance with American College of Car-
diology/American Heart Association guidelines and indications for valve
replacement in patients with aortic stenosis.7,8 Preoperative demographic
information and perioperative events were stored in a computerized
database. Fourteen surgeons of the Division of Cardiothoracic Surgery,
Washington University in St Louis, performed the procedures at Barnes–
Jewish Hospital. Although approaches varied among surgeons, all
procedures were done with cardiopulmonary bypass with mild systemic
hypothermia (30C–34C). Myocardial protection was achieved with
cold blood cardioplegia. The procedures were performed with either
a standard or partial median sternotomy. The selection of valve
prosthesis type was at the discretion of the operating surgeon. There has
been a strong institutional preference for biological valves in patients
older than 65 years and in younger patients who want to avoid
coumadin. Coronary artery bypass grafts (CABG) were performed for
recognized indications in 428 patients.
Patients were evaluated prospectively for the presence PH (systemic
pulmonary artery pressure [sPAP]  35 mm Hg) or absence of PH (sPAP
of<35 mm Hg) by either echocardiography or right heart catheterization.
These were recorded and entered prospectively into the database. Forty-
seven percent (506/1080) of patients had PH. Patients with PHwere further
subdivided into groups of mild (sPAP 35–44 mmHg), moderate (sPAP 45–
59 mm Hg), or severe (sPAP  60 mm Hg). Mean duration of follow-up
was 4.5 3.5 years for patients without PH and 3.4 3.2 years for patients
with PH. Overall mean follow-up was 4.0  3.4 years. Echocardiographic
follow-up consisted of those patients who survived surgery and had postop-
erative echocardiograms (284/1008, 28%) at an average of 3.1 2.7 years
after surgery, which were reviewed for assessment of sPAP.
Operative mortality was defined as death within 30 days or before dis-
charge from the hospital. Preoperative, operative, and postoperative vari-
ables including operative mortality were compared between the early
and late eras in the study: the early group underwent surgery from JanuaryThe Journal of Thoracic and Carof 1996 through December 31, 2002 (7 years, 172 patients) and the late
group of patients had surgery from January 1, 2003, through June 30,
2009 (6.5 years, 334 patients). Continuous data are expressed as mean 
standard deviation and categorical data are expressed as counts and propor-
tions. The Kaplan–Meier estimate was used to depict survival over time
among operative survivors. The c2 or Fisher exact univariate tests were
used to analyze differences in proportions in the categorical data. Factors
found to trend toward significance (gender, age, PH, isolated AVR, New
York Heart Association class III or IV, myocardial infarction, stroke, left
ventricular ejection fraction (LVEF), systemic hypertension, diabetes,
renal failure, dialysis, atrial fibrillation, hypercholesterolemia, chronic ob-
structive pulmonary disease, previous CABG, body surface area, and intra-
aortic balloon pump at the time of surgery) by univariate testing (P  .10)
were entered into a multivariate analysis. The Cox multivariate propor-
tional hazards regression model was used to identify independent prognos-
tic factors for death. Relative risks (RR) with 95% confidence intervals
were calculated for each of the significant risk factors. All data analysis
was performed using SPSS 11.0 (SPSS Inc, Chicago, Ill) for Windows
(Microsoft Corp, Redmond, Wash).
RESULTS
Compared with patients with normal sPAP, patients with
PH were significantly older (72 vs 70 years old, P ¼ .004),
more often in New York Heart Association class III or IV
(77% vs 59%, P<.001), and had a prior myocardial infarc-
tion (29% vs 19%, P< .001), diabetes (37% vs 23%,
P<.001), hypertension (74% vs 69%, P ¼ .01), and lower
LVEF (46% vs 52%, P<.001) (Table 1). More concomi-
tant procedures were done on patients with PH (51.9% vs
43.5%), and subsequently the cardiopulmonary bypass
time was slightly longer in these patients (160 minutes vs
153 minutes, P ¼ .034). Patients with PH had longer venti-
lation times (26.1 hours vs 16.7 hours, P<.001). Although
they had a higher rate of cerebrovascular accident, this was
not statistically different (4.5% vs 2.8%, P ¼ .14).
Operative mortality was statistically higher in patients
with PH (9.3% vs 5.4%, P ¼ .018). Cox regression multi-
variate analysis demonstrated that mortality was adversely
affected by the presence of renal failure (RR ¼ 2.5,
P<.001), diabetes (RR ¼ 1.7, P<.001), previous cardiac
surgery (RR¼ 1.6, P¼ .001), and PH (RR¼ 1.5, P¼ .002),
as well as age (RR¼ 1.04, P<.001) and LVEF (RR¼ 0 .99,
P ¼ .05) (Table 2).
Evaluation of early versus late era of surgery showed that
preoperative and intraoperative variables were similar ex-
cept for LVEF (40%  16% vs 48%  16%, P<.001),
percentage of patients who underwent isolated AVR (36%
[62 patients] vs 47% [158 patients], P¼ .02), cardiopulmo-
nary bypass time (181  56 minutes vs 149  57 minutes,
P<.001), and crossclamp time (131  47 minutes vs 98 
47minutes, P<.001) in the early versus late groups, respec-
tively. Patients who had surgery in the first 7 years of the
study had an operative mortality of 8.7% (15/172) whereas
for those who underwent surgery in the late era it was 9.6%
(32/334, P ¼ .8).
Survival was further evaluated on the basis of severity of
PH including 4 subgroups: no PH (sPAP< 35 mm Hg,diovascular Surgery c Volume 141, Number 6 1425
TABLE 1. Baseline clinical characteristics
Variable
AVR with PH
(n ¼ 506)
AVR no PH
(n ¼ 574)
P
value
Preoperative variables (%) (%)
Age (y) 72.3  10.7 70.2  13.5 .004
Male gender 299 (59.1) 332 (57.8) .711
NYHA III or IV 390 (77.1) 338 (58.9) <.001
COPD 44 (8.7) 44 (7.7) .578
MI 147 (29.1) 111 (19.3) <.001
Diabetes 188 (37.2) 129 (22.5) <.001
Hypertension 374 (73.9) 384 (66.9) .014
LVEF 46  15 52  13 <.001
Previous CPB surgery 107 (21) 88 (15) .014
Operative variables
Isolated AVR 220 (43.5) 298 (51.9) .003
Concomitant procedures
CABG  other 193 209
CABGþMVR 21 5
MV  other 38 9
Other 34 52
CPB time 160  57 153  54 .034
Aortic crossclamp time 109  45 106  40 .297
Postoperative variables
Prolonged ventilation 132 (26.1) 96 (16.7) <.001
CVA 23 (4.5) 16 (2.8) .142
Atrial fibrillation/flutter 180 (36) 201 (35) .849
Placement of IABP 56 (11) 15 (3) <.001
Operative mortality 47 (9.3) 31 (5.4) .018
Median LOS (d) 8 (6–84) 7 (6–91) .001
Total follow-up (y) 3.4  3.2 4.4  3.5 <.001
Continuous data are presented as mean  standard deviation. AVR, Aortic valve
replacement; PH, pulmonary hypertension; NYHA, New York Heart Association
Functional Heart Failure class; COPD, chronic obstructive pulmonary disease; MI,
myocardial infarction; LVEF, left ventricular ejection fraction; CPB, cardiopulmo-
nary bypass; CABG, coronary artery bypass graft; MVR, mitral valve repair or re-
placement; MV, mitral valve; CVA, cerebrovascular accident; IABP, intra-aortic
balloon pump; LOS, length of stay. Other operations include tricuspid valve, pulmo-
nary valve, atrial septal defect, ventricular septal defect, and surgery for arrhythmia.
TABLE 2. Multivariate Cox regression analysis of risk factors for
decreased survival after AVR for aortic stenosis (n ¼ 1080)
Variable N RR 95% CI P value
Pulmonary hypertension 506 1.51 1.160–1.965 .002
Age (y) 1080 1.036 1.020–1.051 <.001
Diabetes 317 1.697 1.120–3.875 <.001
Renal failure 93 2.505 1.613–3.890 <.001
Dialysis 40 2.083 1.308–2.202 .020
NYHA class III or IV 728 1.507 1.101–2.061 .010
LVEF (%) 876 0.991 0.983–1.000 .049
Previous cardiopulmonary bypass 195 1.631 1.210–2.198 .001
Factors found to trend toward significance (gender, age, pulmonary hypertension,
isolated aortic valve replacement [AVR], New York Heart Association [NYHA] class
III or IV, myocardial infarction, stroke, left ventricular ejection fraction [LVEF], sys-
temic hypertension, diabetes, renal failure, dialysis, atrial fibrillation, hypercholester-
olemia, chronic obstructive pulmonary disease, previous cardiac surgery requiring
cardiopulmonary bypass, body surface area) by univariate testing (P  .10) were
analyzed. Gender, isolated aortic valve replacement, myocardial infarction, stroke,
systemic hypertension, atrial fibrillation, hypercholesterolemia, chronic obstructive
pulmonary disease, and body surface area were not found to be significant indepen-
dent predictors for lower survival after aortic valve replacement for aortic stenosis in
the mitral valve model. RR, Relative risk; CI, confidence intervals.
FIGURE 1. Kaplan–Meier survival curve based on preoperative pulmo-
nary artery pressure. Number at each time point is depicted at the bottom
of the graph.
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Dn¼ 66), mild PH (sPAP 35–44 mm Hg, n¼ 125), moderate
PH (sPAP 45–59 mm Hg, n¼ 129), and severe PH (sPAP
60mmHg, n¼ 102). Kaplan–Meier analysis of patientswith
preoperative PH showed that survival was significantly
worse in the more severe PH groups (P ¼ .020) (Figure 1).
Similarly, analysis was completed using measurements of
patients’ postoperative sPAP, demonstrating that 5-year
survival was diminished in thosewithmore severe PH versus
thosewithmild or no PH (45% vs 78%,P<.001) (Figure 2).
Evaluation of patients with high pulmonary vascular
resistance (PVR) was done by calculating the PVR using
pulmonary artery pressure (PAP), LVEDP, and cardiac out-
put (CO): (mean PAPLVEDP)/(CO) and then evaluating
survival comparing patients with PVR of less than 3
Wood units versus those with 3 Wood units or more. Ka-
plan–Meier analysis showed that survival was decreased
in those with higher PVR (5-year survival 49% vs 72%,
P ¼ .001) (Figure 3).1426 The Journal of Thoracic and Cardiovascular SurPatients with mild PH showed no improvement in sPAP
when comparing postoperativemeasurements with preoper-
ative (P¼ .22) (Table 3). In contrast, sPAP fell after AVR in
patients with moderate PH (51  4 mm Hg vs 45  16 mm
Hg, P ¼ .01), with an even more substantial fall in patients
with severe PH (69  12 mm Hg vs 45  14 mm Hg,
P<.001) (Table 3).
To eliminate potential conflicting impact of associated
mitral valve and other valvular diseases, we repeated the
analysis, looking specifically at patients who underwent
only AVR or AVR þ CABG, excluding all the patients
who had concomitant valve surgery. In this group of patients
(n¼ 978 patients) we found similar changes: operativemor-
tality was 5.2% (28/542) in those with no PH, whereas for
those with PH it was 8.0% (35/436, P ¼ .08). The fall ingery c June 2011
FIGURE 2. Kaplan–Meier survival curve based on postoperative pulmo-
nary artery pressure. Number at each time point is depicted at the bottom of
the graph. FIGURE 3. Kaplan–Meier survival curve based on preoperative pulmo-
nary artery vascular resistance. Number at each time point is depicted at
the bottom of the graph.
Melby et al Acquired Cardiovascular DiseasesPAP for those with PH was similar to that for the overall
group as well (preoperative sPAP 50.1 mm Hg  13.5
mmHg fell postoperatively to 41.1 mmHg 13.5 mmHg).TABLE 3. Change in systolic pulmonary artery pressure after aortic
valve replacement in patients with mild, moderate, and severe
pulmonary hypertension
Group
Mean
preop sPAP
Mean
postop sPAP
P
value
35–44 mm Hg (n ¼ 61) 39  3 37  11 .218
45–59 mm Hg (n ¼ 58) 51  4 45  16 .014
60 mm Hg (n ¼ 46) 69  12 45  14 <.001
Overall group 51  14 42  14 <.001
preop, Preoperative; postop, postoperative; sPAP, systolic pulmonary artery pressure.
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PH is common among patients who undergo AVR for ste-
nosis.4,6,9 In this study, PH was present in 47% of patients
who underwent AVR. Despite this, there have been no large
scale studies that have delineated the risks of this
comorbidity or what the outcomes are after AVR.
Furthermore, the presence of any PH is not considered in
major preoperative risk assessment tools available. The
EuroSCORE uses only the presence of severe PH (PAP>
60 mm Hg) and the Society of Thoracic Surgeons risk
calculator does not consider PH at all.10-12
Several small observational studies have shown improve-
ment in outcome for patients who underwent AVR with PH
compared with medically treated patients. Malouf and asso-
ciates3 compared 37 patients with severe PH who under-
went AVR with a group of 10 similar patients who were
treated medically. In that study there was improved survival
at 5 years (52% vs 20%). In another retrospective study by
Pai and colleagues,5 36 patients with severe aortic stenosis
and PH underwent surgery and were compared with 83 who
were treated medically. After adjustment for comorbidities,
the authors found an improvement in 5-year survival (65%
vs 20%) compared with the nonoperative group. These
studies demonstrated better outcomes in patients undergo-
ing AVR versus medical therapy alone; however, the num-
ber of patients in these studies was small and comparison
between groups was difficult because many of the medi-
cally treated patients were likely deemed inoperable owing
to comorbidities. In a study of 92 patients by Johnson and
coauthors,2 13 of 15 patients with severe PH underwent
AVR for stenosis and there was no operative mortality. In
a study by Tracy, Proctor, and Hizny,4 37 of 52 (70%)
patients undergoing AVR for aortic stenosis had PH, withThe Journal of Thoracic and Caran operative mortality of only 1.9%. From these small stud-
ies it was difficult to draw adequate conclusions about oper-
ative mortality in patients with PH. In the current report,
operative mortality was nearly twice as high when PH
was present (9.3% vs 5.4%), similar to previous reports.10
Because survival is influenced by the presence of PH, and
because more than 200,000 AVRs are done annually world-
wide, determination of its incremental risk is warranted.11
Historical studies have shown that patients with PH have
worse outcomes after AVR for aortic stenosis. Copeland
and others9 showed in an early report of 1127 patients un-
dergoing isolated AVR that the presence of mean PAP of
30 mm Hg or more (n ¼ 173) decreased long-term survival
compared with those with a mean PAP less than 30
(n¼ 492, P¼ .006). We similarly found that in the presence
of preoperative PH, long-term survival is compromised. In
this study, the degree of PH affected adversely the long-
term survival, inasmuch as those with moderate and severe
PH had only 57% and 52% 5-year survivals whereas those
with no or mild PH had 68% and 62% 5-year survivals. In
addition, thosewith persistent postoperativemoderate or se-
vere PH also had even worse 5-year survival (45%–64%)
than did those without or with mild postoperative PH
(77%–78%, Figure 1).diovascular Surgery c Volume 141, Number 6 1427
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travenous milrinone, inhaled nitric oxide, sildenafil, and
other modalities, have ameliorated some of the physiologic
consequences of PH.12-14 Almost half of patients
undergoing surgery for aortic stenosis have PH (in both
this and other studies),4,6,9 and therefore continued efforts
to improve the treatment of these patients is warranted.
Our current first-line treatment strategy for patients with
PH is typically inhaled epoprostenol with concurrent inotro-
pic support as the intraoperative or postoperative hemody-
namics warrant (ie, elevated PAPs and evidence of or
concern for right heart failure). Inhaled nitric oxide is not
used as a first-line agent despite its efficacy owing to cost
considerations. Inhaled pulmonary vasodilator therapy is
usually continued for the first 24 hours and then weaned
as right heart function tolerates. Inotropic therapy is usually
maintained until pulmonary vasodilator therapy is weaned
substantially or discontinued. Rarely, long-term oral medi-
cations are administered (ie, sildenafil or bosentan) and
usually only in patients previously taking these drugs.
These treatment strategies are used for management of
PH in general and are not unique to patients undergoing
AVR inasmuch as little scientific evidence is available on
improvement in outcomes after AVR.
A transcatheter approach for the treatment of aortic ste-
nosis is being performed for high-risk patients at several
centers throughout the world. The mortality rate for this
procedure was higher in the presence of PH in 1 study: in
345 procedures on 339 patients, the relative risk of mortality
within 30 days was 2.1 for patients with PH.15 PH has also
been found to be a risk factor in octogenarians undergoing
cardiac operations.16 Preoperative risk assessment is an im-
portant part of the decision-making process of whether pa-
tients should undergo a surgical or transcatheter valve
implantation procedure for aortic stenosis. Although it has
been shown that high-risk patients can successfully undergo
surgery, including the elderly and patients with other co-
morbidities,17-19 an accurate risk assessment is critical to
an informed discussion between the surgeon and patient
so that appropriate decisions can be made as to whether
an intervention should be performed and which approach
should be undertaken. The current study demonstrated
that operative mortality nearly doubled in the presence of
PH, and 5-year survival was significantly diminished in
those with severe preoperative PH versus those with mild
or no PH (52% vs 60%–68%, respectively).
Multiple factors can contribute to and influence PAPs,
including PVR, right heart function, and left ventricular
systolic and diastolic function. It remains unclear whether
some underlying causes or consequences of PH may
contribute more to the adverse outcomes observed. For ex-
ample, elevated LVEDP has also been shown to be an inde-
pendent risk factor in coronary cardiac surgery.20 This study
demonstrated that survival was decreased in the presence of1428 The Journal of Thoracic and Cardiovascular SurPVR. PVR is another measurement that is often used to
describe the severity of the pulmonary vascular disease in
patients with PH. The equation that describes it is as fol-
lows: PVR ¼ (mean PAP – PAWP [LVEDP]/CO) 3 80
(this gives PVR in dyn-s/cm5), where PAWP is pulmonary
artery wedge pressure and CO is cardiac output. For
Wood units, the following is used: mean PAP (PAWP/CO).
Those with a PVR of more than 3 Wood units had 49%
5-year survival versus those with normal PVR, who had
72% 5-year survival. The presence of increased PVR
clearly portends a worse outcome. The different causes of
PH (eg, whether it is due to cardiac disease or whether it
is from pulmonary disease) may influence outcomes differ-
ently. However, elevated PVR is sometimes due to intrinsic
lung vascular disease, but can also be an effect of long-term
elevated LVEDPs. This current study evaluated a heteroge-
neous group of patients with PH from multiple causes,
likely including some individuals with PH owing to ele-
vated LVEDP as well as other patients who had PH owing
to lung disease or to intrinsic pulmonary vascular disease.
Further studies need to be done to elucidate which preoper-
ative variables associated with PH, including etiology,
affect survival. The presence of elevated PVR likely plays
a critical role.
Limitations
Retrospective studies have inherent limitations. Follow-
up was not complete in all 1080 patients. However, there
were sufficient numbers included in the study to determine
outcomes in groups both with and without PH. Several sur-
geons were involved during this 13-year period, which
could increase the variability of the data. The large number
of surgeons would, however, limit the effect that surgeon-
dependent factors might have had on outcomes. Echocar-
diographic studies used estimations of PAP whereas the
catheterization methods used direct measurements; the esti-
mation method may have decreased the overall accuracy of
the PAP measurements. Furthermore, echocardiography
and catheterization data were not collected on every patient
owing to the large number of patients over the extended
study period. This could introduce selection bias for sicker
patients who may undergo more extensive studies such as
echocardiography or catheterization allowing identification
of PHmore often in this group of patients with more comor-
bidities.
Inclusion of patients with mitral valve disease severe
enough to warrant surgical intervention may be considered
a confounding factor. However, analysis of mortality and
major morbidity after excluding this group of patients
yielded results very similar to the analysis of those who
had mitral valve disease. As the etiologies of PH are likely
multifactorial in many cases, inclusion of these patients bet-
ter represents the real-world scenario of thosewho need sur-
gery for severe aortic stenosis. Further studies are needed togery c June 2011
Melby et al Acquired Cardiovascular Diseaseelucidatewhich causative factors of PH have the highest im-
pact on outcome.SUMMARY
In patients undergoing AVR for aortic stenosis, PH
increased operative and long-term mortality. Earlier
intervention—before irreversible changes in the pulmonary
circulation can occur—should be considered for asymptom-
atic or minimally symptomatic patients with significant aor-
tic stenosis and moderate to severe PH. It is important for
surgeons to consider PH in preoperative risk assessment
of patients undergoing AVR.A
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Dr James S. Gammie (Baltimore, Md). Dr Melby and col-
leagues from Washington University are to be congratulated on
a well-presented study. Previous work has clearly demonstrated
that unoperated aortic stenosis with PH is associated with a partic-
ularly dismal prognosis. It is also clear from the literature that
development of PH in patients with aortic stenosis is associated
with the presence of symptoms, a decline in left ventricular sys-
tolic ejection performance, and, most importantly and closely,
with diastolic dysfunction as measured by elevated LVEDP and
echocardiographic indices of impaired left ventricular relaxation.
PH has not been included in risk models assessing the outcomes
after AVR, and thus this work contributes to the literature. The cur-
rent Society of Thoracic Surgeons risk models do not include PAP
because this variable is infrequently collected, and, in fact, in re-
cent years has only been collected in 30% of patients. There is
clear room for improvement here.
I would like to emphasize a key finding of your study, which
was more clear in the manuscript than in the presentation: your
multivariable models demonstrated that the presence of PH was
not a risk factor for perioperative mortality, and thus we can
conclude that PH in patients with aortic stenosis compromises
long-term survival but not short-term surgical outcomes.
Your study was heterogeneous in that it included both isolated
AVRs as well as AVRs performed with CABG. Did you look at
your isolated aortic valve population and did you find that PH
had a similar impact on outcomes?
Dr Melby. Thank you, Dr Gammie. With respect to the perio-
perative mortality, our perioperative mortality did almost double,
but the review with multivariate analysis did not show that it
was an independent risk factor. We did not have the chance to
go back—and it is certainly something we will look at in the fu-
ture—to look at just the patients who had only AVR. As you
saw, that was about half of our patients. We have encountered
the problem that you mentioned, which is that it is not a frequently
reported number. As you start to cut your group down, you start to
lose patients and you have weaker results. We looked at the entire
group and not exclusively at those who had only AVR, but
certainly that would be worth looking at in the future.diovascular Surgery c Volume 141, Number 6 1429
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DDr Gammie. Did you look separately at your subset of patients
that had more significant PH, those that you classified as moderate
or severe?
DrMelby.Whenwe did our Kaplan–Meier analysis, we created
categories of mild, moderate, and severe PH and found that those
with more significant PH indeed had a significantly worse long-
term survival. When we looked at the perioperative mortality,
once again, it was not a significant independent risk factor,
although it was a significant univariate risk factor. Likely, the in-
creased risk of perioperative death is associated with the multiple
comorbidities.
Dr Gammie. This series spanned 13 years, during which time
greater use of nitric oxide and intravenous phosphodiesterase in-
hibitors occurred. In addition to these modalities, there are now
3 classes of oral medications available to treat PH, including pros-
tacyclins, endothelin receptor antagonists, and oral phosphodies-
terase inhibitors. Given your findings and the impressive fact
that half of these patients are dead 5 years after surgery, do you
think that we should consider treating these patients after heart
valve surgery much as we treat post-CABG patients, with statins?
Also, do you think these results would have an impact on indica-
tions for AVR?
Dr Melby. Thank you. Indeed, we have been treating PH more
aggressively and using some of the medications that you men-
tioned, nitric oxide and epoprostenol, or Flolan, commonly in
the postoperative period. Unfortunately, there is very little litera-
ture on this and no one has looked specifically at the question
you asked. We have looked at our data and recognize that these
are important questions, specifically who needs to be treated. We
are trending toward looking preoperatively more on patients
with PH if they react to some of these medications because it
seems to be a trend that if you get a nitric challenge and your
PAP does not fall, you do more poorly with surgery. However,
these are difficult questions that are going to require more studies.
We have not done such studies yet, but we need to do so.
Dr Randall B. Griepp (New York, NY). You define PH in terms
of PAP rather than the resistance across the pulmonary vascular
bed, and consequently it has both the component of PVR per se
as well as left ventricular filling pressure. I wonder whether
a good part of this effect may just be that you are measuring a sur-
rogate for left ventricular failure, either the dilated systolically
failing ventricle or the very hypertrophied diastolically dysfunc-
tioning ventricle. That might also be an explanation as to why1430 The Journal of Thoracic and Cardiovascular Surthose patients whose PAP does not change postoperatively do so
poorly. I might suggest that perhaps those are the ones with the se-
verely hypertrophied ventricles in whom the major issue is really
diastolic dysfunction, which does not clear very quickly.
Dr Melby. Thank you. I appreciate those comments. From my
slides, I can show you a graph indicating that we indeed looked at
patients with increased PVR, trying to answer the exact question
you are asking. Those with an elevated PVR we have separated
into greater than 3 Wood units or less than 3 Wood units, trying
to tease out what is the left ventricular involvement in this. Those
with the higher PVR also did worse, similar to the response of the
group with just high PH.
Dr Kevin D. Accola (Orlando, Fla). Dr Melby, to elaborate on
Drs Gammie and Griepp’s comments, can you apply this clinically
now? How have you looked at your patients, particularly those
with severe PH? Have you designed a strategy clinically to preop-
eratively evaluate these or use provocative testing to see which
patients truly have reactive PH relative to their left ventricular
dysfunction or truly fixed PH, which I think is another subset
and particularly a higher risk category?
DrMelby. That is an excellent question. We have indeed begun
to implement some of these findings in our preoperative workup
and we have had provocative testing. However, there is very little
published on this, and it is mostly just done by the feelings of the
individual surgeon and by our preoperative planning team. We
happen to have a nice preoperative planning group devised of an-
esthesiologists who are very interested in PH. We have looked at
this in some patients, and it only takes a few cases of severe PH
to go bad for you to realize there is something different with these
patients. Thus we are trying to tease those patients out and find out
which ones might be higher risk. I do not have any great answers
yet, but it is certainly something that needs to be looked at.
Dr Irene Cybulsky (Hamilton, Ontario, Canada). Have you
looked at the etiology of the PH, whether it was cardiac or respi-
ratory? Also have you looked at associated tricuspid regurgitation
with the degree of PH?
Dr Melby. That is a very good question, and you bring up
a good point in that the etiology of PH can be multifactorial.
Unfortunately with the database that we have, there is just no
way to find all the answers to the questions you ask. Once again,
there is a paucity of literature on this, and this is a great opportunity
to find out which factors are going to tease out to be the most
significant ones.gery c June 2011
